Use of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF)
Trial statusNot yet recruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age10-80
SponsorEbima Clifford Okundaye
About this trial
Use of QRX-3 in hospitalized patients with pediatric and adult patients with acute tubular necrosis renal failure
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Hospitalized patients
presence of Acute renal failure
Nephrologist diagnosis of Acute tubular necrosis or fractional excretion of sodium of >2%
willingness to participate
Disqualifiers
None
Trial design
Design model
Parallel
Treatments tested in this trial
QRX-3
DrugCombination of QRX-3 with standard therapy will be given to one arm in trial , another arm will receive placebo
Treatment groups
500 Participants
are divided into 2 treatment groupsGroup A: Use of QRX-3 in addition to standard therapyExperimental treatment 1 intervention
Group B: control groupPlacebo comparator 1 intervention
Trial outcomes
Primary outcomes
1
Rate of change in creatinine glomerular filtration rate
compare the outcome effect of added QRX-3 drug to placebo in addition to standard therapy on the rate of change from baseline of creatinine GFR in ATN patients
Time frame
28 daysSecondary outcomes
1
daily change in glomerular filtration rate in ml/min
daily change in GFR by creatinine in mls/min
Time frame
7 days2
daily change in cystatin C level in mg/dl
daily change in measured cystatin C level
Time frame
7 daysOther outcomes
1
effect of QRX-3 on recovery of renal function in patients with ATN renal failure
comparism of number of patient achieving return to baseline renal function in both groups
Time frame
28Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Ebima Clifford Okundaye
Lead sponsor
Neukidney Inc.
Sponsor institution
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: